Stroke is the second highest disease causing burden on the global economy and one
of the leading causes of non-traumatic disability [
[1]
]. As many as 30–40% of ischemic stroke cases have no identified medical cause, known
as cryptogenic stroke (CS) [
[2]
]. Within the last century, the incidence of patent foramen ovale (PFO) in patients
with CS is as high as 50–60%, which is significantly higher than 20–30% in the normal
population [
[3]
]. In the past two decades, to explore the effective treatment of patients with CS
and PFO, several related experiments have been conducted in the academic community.
After contradictory views and negative results, it was finally confirmed that closure
therapy can significantly reduce the risk of stroke recurrence [
4
,
5
,
6
]. However, literature on the Asian population with a high incidence of stroke, particularly
on biomarkers for risk factors for stroke recurrence, is currently lacking.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Measuring the global burden of disease[J].N Engl J Med. 2013; 369: 448-457https://doi.org/10.1056/NEJMra1201534
- Embolic strokes of undetermined source: the case for a new clinical construct[J].Lancet Neurol. 2014; 13: 429-438https://doi.org/10.1016/S1474-4422(13)70310-7
- Patent foramen ovale: current pathology, pathophysiology, and clinical status[J].J Am Coll Cardiol. 2005; 46: 1768-1776https://doi.org/10.1016/j.jacc.2005.08.038
- Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J].N Engl J Med. 2017; 377: 1011-1021https://doi.org/10.1056/NEJMoa1705915
- Long-Term outcomes of patent foramen ovale closure or medical therapy after stroke[j].N Engl J Med. 2017; 377: 1022-1032https://doi.org/10.1056/NEJMoa1610057
- Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[j].New England Journal of Medicine. 2017; 377: 1033-1042https://doi.org/10.1056/NEJMoa1707404
- The risk of paradoxical embolism (RoPE) study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke[J].Trials. 2011; 12: 185https://doi.org/10.1186/1745-6215-12-185
- Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis[j].JAMA. 2002; 288: 2015-2022https://doi.org/10.1001/jama.288.16.2015
- Relation of serum homocysteine levels to cerebral artery calcification and atherosclerosis[J].Atherosclerosis. 2016; 254: 200-204https://doi.org/10.1016/j.atherosclerosis.2016.10.023
Article info
Publication history
Published online: April 16, 2020
Accepted:
April 3,
2020
Received:
March 24,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
